Halozyme Therapeutics Inc.
HALO
Market Cap$6.91B
Close$
$53.37
4.1% downside
Current Fair Value
4.1% downsideOvervalued by 4.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.91 Billion |
|---|---|
| Enterprise Value | $8.24 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $3.5 |
| Beta | 1.26 |
| Outstanding Shares | 123,215,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 14.23 |
|---|---|
| PEG | 26.49 |
| Price to Sales | 6.96 |
| Price to Book Ratio | 18.55 |
| Enterprise Value to Revenue | 7.6 |
| Enterprise Value to EBIT | 13.47 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 3.13 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Halozyme Therapeutics Inc.
CEO: Helen Torley